منابع مشابه
Cox-2 Inhibitors and Cardiovascular Risks
The controversy over the cardiovascular risks of cox-2 inhibitors stems from 2 main trials: VIGOR and CLASS. These two trials were designed to assess the gastrointestinal safety of rofecoxib (Vioxx) and celecoxib (Celebrex), respectively. From these trials, it was observed that the cox-2 inhibitors had a higher number of cardiovascular events than the NSAIDS that they were paired against. For e...
متن کاملRelative thromboembolic risks associated with COX-2 inhibitors.
OBJECTIVE To evaluate the clinical literature on cyclooxygenase-2 (COX-2) inhibitors to determine whether a greater incidence of thromboembolic events is universal within the drug class. DATA SOURCES A MEDLINE search was conducted (1996-March 2005) for key articles in the English language assessing the efficacy or safety of these agents. STUDY SELECTION AND DATA EXTRACTION Randomized, doubl...
متن کاملCOX-2 inhibitors.
Cyclooxygenase-2 (COX-2) inhibitors constitute a new group of non-steroidal anti-inflammatory drugs (NSAIDs) which, at recommended doses, block prostaglandin production by cyclooxygenase-2, but not by cyclooxygenase-1. Two COX-2 inhibitors are currently available in Australia--celecoxib, which is taken twice daily, and rofecoxib, which is taken once daily. Both drugs act rapidly in providing pa...
متن کاملCOX-1 and COX-2 products in the gut: therapeutic impact of COX-2 inhibitors.
Despite the considerable range of newly identified disease modifying approaches to the control of the inflammatory process reported over the past 10–20 years, only a few have yet gained widespread clinical acceptance. In contrast, the very recent advent of the class of anti-inflammatory agents termed COX-2 selective inhibitors is already having a significant impact on current clinical prescribi...
متن کاملCOX-2 inhibitors and breast cancer.
The cyclooxygenase ( COX ) -2 inhibitor celecoxib was recently approved in the USA for the prevention of polyp formation in familial adenomatous polyposis, a defined premalignant condition for colorectal cancer. The potential value of COX inhibitors in similar roles for other malignancies, particularly breast cancer, is therefore currently under intense scrutiny. Use of these medications in che...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Canadian Medical Association Journal
سال: 2007
ISSN: 0820-3946,1488-2329
DOI: 10.1503/cmaj.1060144